Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Vadastuximab Talirine Yields Rapid and Deep Remissions in Early Study of Patients With AML

December 4th 2016

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

December 4th 2016

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

TKI Cessation Strategies Emerging for CML

December 4th 2016

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

Impressive Brentuximab Vedotin Data May Change Practice in CTCL

December 4th 2016

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant

December 4th 2016

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Dr. Kantarjian on Future Role of Chemotherapy in Patients With ALL

December 3rd 2016

Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).

Future Approaches in Advanced Mastocytosis

December 1st 2016

Clinical Experience with Midostaurin in Advanced SM

December 1st 2016

Phase II Trial of Midostaurin in Advanced SM

December 1st 2016

Rationale for Targeting KIT in Advanced SM

December 1st 2016

Current Treatments for Advanced SM

December 1st 2016

Advanced SM: Diagnosis and Initial Treatment Approach

December 1st 2016

Subtypes and Characteristics of Mastocytosis

December 1st 2016

Emerging Targeted Agents in AML

December 1st 2016

The Efficacy of Midostaurin in Subsets of AML

December 1st 2016

AML: The RATIFY Clinical Trial

December 1st 2016

The Rationale of FLT3 Inhibition in AML

December 1st 2016

FLT3 Mutation Status in AML

December 1st 2016